[The effect of tri-modality therapy on the treatment of muscle-invasive bladder cancer].

Objective: To explore the effect of radical TURBT combing with concomitant chemo-radiotherapy for muscle-invasive bladder cancer (MIBC). Methods: From 2010 to 2015, 73 patients were diagnosed as MIBC, in which 28 patients (TMT Group) received tri-modality bladder sparing treatment, including 21 males and 7 females, mean age (68.9±8.9) yr. There were 16 cases of T(2), 12 cases of T(3). 45 patients (RC Group) received radical cystectomy (RC), including 32 males and 13 females, mean age (66.3±9.6) yr. There were 25 cases of T(2), 18 cases of T(3) and 2 cases of T(4a). The effect of two treatment modality and influence for patient's life quality were retrospective analysis. Results: The overall survival (OS) rate of TMT group was 64.3%, cancer specific survival (CSS) rate was 78.6%. And the OS rate of RC group was 66.7%, CSS rate was 82.2%. There was no statistical difference between two groups. The life quality of TMT group was better than that of RC group. Conclusion: In strict control of indication criterion, rigorous postoperative follow-up and timely salvage radical cystectomy, tri-modality therapy can be used as a new option of muscle-invasive bladder cancer.

[Selective bladder preservation in muscle-invasive bladder cancer by transurethral resection combined with intravesical instillation therapy: analysis of clinical effect in the elderly].

OBJECTIVE: To explore the therapeutic effect and quality of life in elderly patients of muscle-invasive bladder cancer by transurethral resection combined with intravesical instillation therapy. METHODS: From January 2005 to January 2015, 136 cases were diagnosed with T2 bladder cancer by transurethralplasmakinetic therapy or transurethral laser therapy. The data of 136 cases were analyzed retrospectively. RESULTS: In transurethralplasmakinetic therapy group, the overall survival rate was 73.3%, the cancer-specific survival rate was 85.6%, the average survival time were 65 months. In transurethral laser therapy group, the overall survival rate was 73.9%, the cancer-specific survivalrate was 87.2%, the average survival time were 70 months. Two methods also can improve the patient's quality of life. CONCLUSION: For the aged with invasive bladder cancer (T2), we could try the transurethral resection combined with intravesical instillation therapy.